Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
Robert Babb, River Edge, NJ (US); Alina Baum, Pleasantville, NY (US); Gang Chen, Yorktown Heights, NY (US); Cindy Gerson, Irvington, NY (US); Johanna Hansen, Greenwich, CT (US); Tammy Huang, Cross River, NY (US); Christos Kyratsous, Irvington, NY (US); Wen-Yi Lee, New Hyde Park, NY (US); Marine Malbec, Port Chester, NY (US); Andrew Murphy, Croton-on-Hudson, NY (US); William Olson, Yorktown Heights, NY (US); Neil Stahl, Carmel, NY (US); and George D. Yancopoulos, Yorktown Heights, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 19, 2021, as Appl. No. 17/207,524.
Application 17/207,524 is a continuation of application No. 17/021,286, filed on Sep. 15, 2020, granted, now 10,954,289.
Application 17/021,286 is a continuation of application No. 16/996,297, filed on Aug. 18, 2020, granted, now 10,975,139.
Application 16/996,297 is a continuation of application No. 16/912,678, filed on Jun. 25, 2020, granted, now 10,787,501.
Claims priority of provisional application 63/034,865, filed on Jun. 4, 2020.
Claims priority of provisional application 63/025,949, filed on May 15, 2020.
Claims priority of provisional application 63/014,687, filed on Apr. 23, 2020.
Claims priority of provisional application 63/004,312, filed on Apr. 2, 2020.
Prior Publication US 2022/0356230 A1, Nov. 10, 2022
1. A vector comprising a polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said HCVR comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 640.